Phase 3 Patient Enrollment Milestone
Resolves: Successful enrollment of first 50 patients in Phase 3 trial
sec_filing· Clinical Trial Progress
Phase 3 Patient Enrollment Milestone
Market overview
Derived from Keros Therapeutics, Inc. (KROS) (CIK 0001664710) 8-K filing analysis
Clinical Trial Progress prediction market
- Implied probability (Yes)
- 75%
- Closes
- 2027-09-30
About this prediction
Resolution criteria
Successful enrollment of first 50 patients in Phase 3 trial
More Clinical Trial Progress markets
No one's made a Conviction call on this yet. Be the first to call it →
Loading…